Price$311.41+1.95 (+0.63%)
01:30 PM07:45 PM
News · 26 weeks86-89%
2025-10-262026-04-19
Mix3790d
- Insider17(46%)
- SEC Filings11(30%)
- Other3(8%)
- Earnings2(5%)
- Offering2(5%)
- Analyst1(3%)
- Other1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Krikorian Lazarus4 - Cencora, Inc. (0001140859) (Issuer)
- PRCencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings ReleaseCencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call v
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cencora Inc.SCHEDULE 13G/A - Cencora, Inc. (0001140859) (Subject)
- SECCencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cencora, Inc. (0001140859) (Filer)
- PRCencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina BusinessCencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora's Retina Consultants of America ("RCA"), a leading management services organization (MSO). "Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians that provides high quality patient care," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "By joining RCA, these physicians will become part of an organization
- SECCencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cencora, Inc. (0001140859) (Filer)
- PRCencora Announces Financial Leadership TransitionCencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de
- INSIDERExecutive Vice President Battaglia Silvana converted options into 8,415 shares and covered exercise/tax liability with 3,673 shares, increasing direct ownership by 25% to 23,566 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERExecutive Vice President Campbell Elizabeth S converted options into 12,623 shares and covered exercise/tax liability with 5,842 shares, increasing direct ownership by 28% to 30,706 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERChief Financial Officer Cleary James F covered exercise/tax liability with 5,409 shares and converted options into 12,623 shares, increasing direct ownership by 5% to 160,357 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Cooper Ellen was granted 692 shares, increasing direct ownership by 13,840% to 697 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Nally Dennis M was granted 655 shares, increasing direct ownership by 5% to 12,959 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Tyler Lauren M was granted 641 shares, increasing direct ownership by 21% to 3,710 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Baumann Werner was granted 557 shares, increasing direct ownership by 18% to 3,687 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Clyburn Frank was granted 557 shares, increasing direct ownership by 48% to 1,724 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Durcan Dermot Mark was granted 905 shares, increasing direct ownership by 4% to 23,767 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Greenberg Lon R was granted 557 shares, increasing direct ownership by 3% to 18,408 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Kim Lorence H. was granted 557 shares, increasing direct ownership by 16% to 4,081 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Miller Redonda was granted 557 shares, increasing direct ownership by 17% to 3,751 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERDirector Ryerkerk Lori was granted 557 shares, increasing direct ownership by 108% to 1,073 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- SECCencora Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Cencora, Inc. (0001140859) (Filer)
- INSIDERPresident & CEO Mauch Robert P. exercised 3,762 shares at a strike of $86.09 and sold $1,350,332 worth of shares (3,762 units at $358.94) (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- INSIDERPresident & CEO Mauch Robert P. sold $479,160 worth of shares (1,333 units at $359.46), decreasing direct ownership by 2% to 65,393 units (SEC Form 4)4 - Cencora, Inc. (0001140859) (Issuer)
- SECCencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cencora, Inc. (0001140859) (Filer)
- PRCovetrus and MWI Animal Health to MergeCombination of companion animal distribution, production animal distribution and technology platforms will make animal healthcare more accessible and affordable Transaction unites complementary businesses to deliver innovative, efficient solutions and expertise across the entire animal health ecosystem Deal values MWI at an enterprise value of $3.5 billion. Cencora to receive cash proceeds of $1.25 billion and $800 million of preferred equity while retaining a non-controlling common equity stake of 34.3% in the combined company Cencora reaffirms fiscal 2026 financial guidance Cencora (NYSE:COR) and Covetrus, a global animal health technology and services company, today announce